NCT00290992CompletedPhase 2
Open-Label, Multi-Center Study of SR29142 as Uricolytic Therapy/Prophylaxis for Hyperuricemia in Pediatric Patients With Newly Diagnosed Hematological Malignancies at High Risk for Tumor Lysis Syndrome
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Sanofi
- Enrollment
- 30
- Locations
- 1
- Primary Endpoint
- Patients with a plasma uric acid level decreased to the endpoint by 48 hr after the start of first drug infusion and lasting until 24 hr after the start of final (Day 5) drug infusion.
Study Overview
Brief Summary
Primary: To estimate efficacy of SR29142 to the pediatric patients with newly diagnosed hematological malignancies at high risk for Tumor Lysis Syndrome, by evaluation of plasma uric acid concentration.
Secondary: To investigate the safety in this population and anti-SR29142 antibodies, anti-SCP antibodies, and pharmacokinetic parameters.
Study Design
- Study Type
- Interventional
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- — to 17 Years (Child)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •<18 years of age
- •Patient with newly diagnosed hematological malignancies presenting with hyperuricemia:
- •Uric acid > 7.5 mg/dL in patients ≥ 13 years old- Uric acid > 6.5mg/dL in patients <13 years old
- •Or, patient with newly diagnosed hematological malignancies presenting with high tumor burden defined:
- •Non-Hodgkin's lymphoma, Stage IV regardless of uric acid level,
- •Non-Hodgkin's Lymphomas stage III regardless of uric acid level with one of the following:
- •At least one lymph node or mass >5 cm in diameter
- •LDH ≥ 3 x ULN (IU/L): Judging according to modified Murphy's classification
- •Acute leukemia with white blood cell count (WBC) ≥ 50,000/mm3 or LDH ≥ 3 x ULN (IU/L) regardless of uric acid level. etc.
Exclusion Criteria
- •Patients who have received or are scheduled to receive other investigational drugs in 30 days prior to the start of SR29142 administration or during the trial period.
- •Low birth weight infant (<2500g) or gestational age <37 weeks
- •Patients who have received or are scheduled allopurinol within 72 hrs prior to the first dose of SR29142 or during the trial period.
- •Known history of severe allergic reaction and/or severe asthma.
- •Known history or family history of glucose-6-phosphate dehydrogenase deficiency.
- •Known history of hemolysis and methemoglobinemia.
- •Severe disorders of liver or kidney. ALT (GPT) > 5.0 x ULN, Total Bilirubin > 3.0 x ULN, Creatinine > 3.0 x ULN
- •Uncontrollable infections (including viral infections).
- •Known positive tests for HBs antigen, HCV antibodies, or HIV-1, 2 antibodies. etc.
Outcomes
Primary Outcomes
Patients with a plasma uric acid level decreased to the endpoint by 48 hr after the start of first drug infusion and lasting until 24 hr after the start of final (Day 5) drug infusion.
Secondary Outcomes
- Safety will be assessed on clinical observation, laboratory test, vital sign (blood pressure, pulse rate and body temperature), and the occurrence of adverse events.
- G6PD activity will be measured in only patients who demonstrate hemolysis.
- Anti-SR29142 antibody and Anti-SCP antibody will be measured.
- PK parameters.
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Active, not recruiting
Phase 2
Phase 2 study of JR-142 in pediatric patients with growth hormone deficiencyGrowth hormone deficiency in childrenJPRN-jRCT2031200372Ryo Ibaraki24
Unknown
Phase 3
Randomized Study of ATG for Graft Versus Host Disease (GVHD) Prevention in Paediatric Patients Given an Unrelated Donor Stem Cell TransplantationPaediatric Patients Affected by Haematological Malignancies and Eligible to Undergo HSCT From an Unrelated VolunteerNCT00934557Fondazione IRCCS Policlinico San Matteo di Pavia42
Completed
Phase 2
Study of the Safety and Tolerability of HPN-100 Compared to Sodium Phenylbutyrate in Children With Urea Cycle DisordersUrea Cycle DisordersNCT00947544Amgen17
Completed
Phase 1
A Study of DSP-7888 in Pediatric Patients With Relapsed or Refractory High Grade GliomasDiffuse Intrinsic Pontine GliomaGlioblastomaNCT02750891Sumitomo Pharma Co., Ltd.18
Completed
Phase 1
A Pediatric Study of a Plerixafor Containing Regimen In Second Allogeneic Stem Cell TransplantationChronic Myeloid LeukemiaNon-Hodgkin's LymphomaAcute Myeloid LeukemiaAcute Lymphoblastic LeukemiaMyelodysplastic SyndromeNCT01068301St. Jude Children's Research Hospital12